Tags

Type your tag names separated by a space and hit enter

Biology and treatment of Burkitt's lymphoma.
Curr Opin Hematol 2007; 14(4):375-81CO

Abstract

PURPOSE OF REVIEW

Burkitt's lymphoma is a unique hematological malignancy remarkable for its biological characteristics, including aberrant expression of the MYC oncogene, and its requirement for intensive treatment regimens. This review will focus on those features, and discuss recent advances in the molecular biology and advancing treatment options for the disease.

RECENT FINDINGS

Advances in molecular biology have provided many new insights into the biology and treatment options for Burkitt's lymphoma. Microarray technology has recently been used to define a molecular gene expression signature for Burkitt's lymphoma. This signature allows for the differentiation of Burkitt's lymphoma from other forms of non-Hodgkin's lymphoma such as diffuse large B-cell lymphoma. Recent advances in the use of biological agents, such as rituximab, have also allowed for a reduction in treatment toxicities while still offering comparable survival outcomes for patients.

SUMMARY

Burkitt's lymphoma is an interesting mature B-cell non-Hodgkin's lymphoma that has numerous distinct features and clinical variants depending on factors such as geographical location, immunological status and patient's age. Although the role of the MYC oncogene has been well studied, we are only now appreciating the defining molecular characteristics of this disease, and using these advances to improve treatment options for patients.

Authors+Show Affiliations

Division of Pediatric Hematology-Oncology, Johns Hopkins University, Baltimore, Maryland 21205, USA. jyustei1@jhmi.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17534164

Citation

Yustein, Jason T., and Chi V. Dang. "Biology and Treatment of Burkitt's Lymphoma." Current Opinion in Hematology, vol. 14, no. 4, 2007, pp. 375-81.
Yustein JT, Dang CV. Biology and treatment of Burkitt's lymphoma. Curr Opin Hematol. 2007;14(4):375-81.
Yustein, J. T., & Dang, C. V. (2007). Biology and treatment of Burkitt's lymphoma. Current Opinion in Hematology, 14(4), pp. 375-81.
Yustein JT, Dang CV. Biology and Treatment of Burkitt's Lymphoma. Curr Opin Hematol. 2007;14(4):375-81. PubMed PMID: 17534164.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Biology and treatment of Burkitt's lymphoma. AU - Yustein,Jason T, AU - Dang,Chi V, PY - 2007/5/31/pubmed PY - 2007/7/7/medline PY - 2007/5/31/entrez SP - 375 EP - 81 JF - Current opinion in hematology JO - Curr. Opin. Hematol. VL - 14 IS - 4 N2 - PURPOSE OF REVIEW: Burkitt's lymphoma is a unique hematological malignancy remarkable for its biological characteristics, including aberrant expression of the MYC oncogene, and its requirement for intensive treatment regimens. This review will focus on those features, and discuss recent advances in the molecular biology and advancing treatment options for the disease. RECENT FINDINGS: Advances in molecular biology have provided many new insights into the biology and treatment options for Burkitt's lymphoma. Microarray technology has recently been used to define a molecular gene expression signature for Burkitt's lymphoma. This signature allows for the differentiation of Burkitt's lymphoma from other forms of non-Hodgkin's lymphoma such as diffuse large B-cell lymphoma. Recent advances in the use of biological agents, such as rituximab, have also allowed for a reduction in treatment toxicities while still offering comparable survival outcomes for patients. SUMMARY: Burkitt's lymphoma is an interesting mature B-cell non-Hodgkin's lymphoma that has numerous distinct features and clinical variants depending on factors such as geographical location, immunological status and patient's age. Although the role of the MYC oncogene has been well studied, we are only now appreciating the defining molecular characteristics of this disease, and using these advances to improve treatment options for patients. SN - 1065-6251 UR - https://www.unboundmedicine.com/medline/citation/17534164/Biology_and_treatment_of_Burkitt's_lymphoma_ L2 - http://Insights.ovid.com/pubmed?pmid=17534164 DB - PRIME DP - Unbound Medicine ER -